Q1 2025 PDS Biotechnology Corp Earnings Call Transcript
Key Points
- PDS Biotechnology Corp (PDSB) initiated the versatile 003 phase 3 clinical trial for Versamune HPV plus pembrolizumab, targeting HPV 16 positive head and neck cancer.
- The trial design, approved by the FDA, includes approximately 350 patients and aims to improve outcomes for a growing population with HPV 16 positive head and neck cancer.
- PDSB announced the addition of new clinical sites, including Mayo Clinic, to the versatile 003 trial, indicating strong institutional support.
- The company reported a decrease in net loss from $10.6 million in Q1 2024 to $8.5 million in Q1 2025, attributed to increased tax benefits and lower operating expenses.
- PDSB secured $11 million in funding through a securities purchase agreement and completed a refinancing of its debt, extending the term to 36 months.
- The company reported a net loss of $8.5 million for Q1 2025, indicating ongoing financial challenges.
- Research and development expenses, although reduced, still amounted to $5.8 million for the quarter.
- The cash balance decreased from $41.7 million at the end of 2024 to $40 million as of March 31, 2025.
- Enrollment and activation of clinical sites for the versatile 003 trial are still in progress, with no public update on patient enrollment numbers.
- The company does not currently provide financial guidance, creating uncertainty about future financial performance.
Greetings and welcome to the PDS Biotech first quarter in 2025 earnings conference call. (operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mike Moyer, lifestyle advisors.
Thank you, sir. You may begin.
Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's first quarter 2025 results and clinical programs update call. I'm joined on the call today by the following members of the company's management team. Dr. Frank Bedu-Addo, Chief Executive Officer, Dr. Kirk Shepard, Chief Medical Officer, and Lars Boesgaard, Chief Financial Officer. Dr. Bedu-Addo will begin with an overview of the company's recent progress in its clinical development program. Mr. Boesgaard will review the financial results for the quarter ended March 31, 2025, and Dr. Shepard will then join the call to help address questions from our covering analysts. As a reminder, during this call, we will be making forward-looking. Statements which are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
